In this article, we will discuss the 8 Oversold Stocks to Buy Right Now.
On June 1, Tom Lee, Fundstrat Managing Partner & Head of Research, and Fundstrat Capital CIO, appeared on CNBC’s ‘Squawk Box’ to discuss the latest market trends. Lee acknowledged the difficult market environment and noted that while 2026 was expected to be a year of turbulence and head fakes, there are still powerful tailwinds for America. These include the AI story and newfound energy independence, which position the US to manage high oil prices. Furthermore, as AI moves downstream, it is benefiting American businesses; Lee explained that S&P earnings for Q1 were $10 higher, amounting to $40 for the year, which, at a 20 multiple, adds 800 points to the S&P. Despite his general bullishness, Lee advised that investors remain vigilant as challenges may persist through December.
Regarding his long-term forecast, Lee maintains that the next two years could see some of the best market activity in history. He attributed this to a confluence of factors, including a US economic growth rate that may accelerate to 4%, a feat he calls astounding for the world’s largest, mature economy. Additionally, the US is a significant exporter of AI products, which are high-value tools for the next 10 to 15 years. He anticipates that capital currently misallocated in private alternatives will move into the public market, and demographic tailwinds, specifically Millennials and Gen Z entering the workforce and inheriting generational wealth, will contribute to significant market gains after 2026.
Lee provided a near-term outlook, suggesting the market could reach 7,700 before experiencing a pullback. He expects June markets to continue building on gains, though not at the pace of May, as money moves downstream into software and AI beneficiaries. Between June and October, however, he warns that the market must digest three major IPOs, navigate potential uncertainty surrounding Kevin Warsh’s new model for inflation, and endure normal seasonality around the midterms. This could lead to a drawdown that might feel like a bear market, similar to the 9% decline experienced between February and April. From October, he believes a very strong rally will commence.
Our Methodology
We used screeners to identify stocks that have declined by at least 30% over the past 3 months but for which analysts see potential to recover (with an average upside potential of at least 30%), and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on June 4.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
8 Oversold Stocks to Buy Right Now
8. Maze Therapeutics Inc. (NASDAQ:MAZE)
Number of Hedge Fund Holders: 47
Maze Therapeutics Inc. (NASDAQ:MAZE) is one of the oversold stocks to buy right now. On May 12, Maze Therapeutics highlighted in their corporate and financial update positive topline data from the Phase 2 HORIZON trial of MZE829. The trial evaluated the oral inhibitor in patients with APOL1-mediated kidney disease/AMKD. The results provided clinical proof-of-concept, showing meaningful reductions in proteinuria across broad patient populations, including those with focal segmental glomerulosclerosis.
Following these findings, the company is preparing to advance MZE829 into a pivotal trial for moderate AMKD patients without diabetes, which is planned for H1 2027. The company is also progressing its clinical pipeline for MZE782, an oral small molecule targeting PKU and chronic kidney disease. Maze expects to initiate Phase 2 proof-of-concept trials for this candidate by mid-2026 for PKU and in the second half of 2026 for CKD, with topline PKU data anticipated in 2027.
These developments are central to the company’s broader strategy of using genetic insights to address high-unmet needs in metabolic and kidney health. Financially, Maze Therapeutics Inc. (NASDAQ:MAZE) maintains a strong position with $528 million in cash and marketable securities, bolstered by an April 2026 registered offering and a $20 million milestone payment. This capital is expected to fund operations into 2029.
Maze Therapeutics Inc. (NASDAQ:MAZE) is a developer of small-molecule precision medicines for the treatment of kidney and metabolic illnesses.
Hedge Fund Resource Center